International Cancer Patient Coalition

Canada



Prostate Cancer Factsheet: Insights & Key Developments

Key Insights on Prostate Cancer Care and Infrastructure

Core Pillars:

1. Infrastructure
2. Treatment Access, Research Funding and Awareness Campaigns
3. Survival Rates, Early Detection and Palliative Care
4. Utilization of Biomarkers
5. Clinical Guidelines
6. Reimbursement
7. Prostate Cancer Screening

Prostate cancer remains one of the most prevalent cancers worldwide, affecting millions of individuals each year. Despite advancements in diagnostics, treatment, and awareness, disparities in access to care, molecular testing, and specialized centers persist.

This factsheet provides a comprehensive overview of key pillars shaping Prostate cancer care, including specialized infrastructure, treatment accessibility, research funding, early detection, and palliative care.

- **Incidence share:** Most common cancer among Canadian men.
- **Incidence rate:** Approximately 90–100 per 100,000 men per year.
- **Total new cases (2022):** Around 25,000+ men.
- **Daily diagnoses (2022):** Approximately 70+ men per day.
- **Deaths (2022):** Around 5,000–6,000 men.
- **5-year survival rate:** Approximately 91%.
- **Most affected age group:** Primarily 65–75 years and above.
- **Screening participation:** No national program; screening is opportunistic with variable uptake.

International Cancer Patient Coalition

Canada

Infrastructure



Strengths

- Canada has a well-distributed network of cancer centers across provinces, supported by a strong public healthcare system.
- Advanced diagnostic tools like MRI-guided biopsy and robotic surgery are widely available in urban and academic hospitals.

Weakness

- **Wait times** for diagnostic imaging and surgery are high in certain provinces (e.g., Ontario, Nova Scotia), often exceeding recommended clinical timelines.
- Access to care in **rural and Indigenous communities** remains uneven due to limited oncology workforce and infrastructure.

Opportunity

- **Telehealth expansion** can support specialist consultation in remote areas.
- Investment in **mobile cancer units** can improve outreach in underserved regions.

Threats

- Regional disparities in infrastructure funding and staffing could worsen with growing cancer burden.
- **Climate-related disruptions** (e.g., wildfires) in provinces like British Columbia have occasionally affected hospital functioning.

5. Advanced nationwide infrastructure, widespread availability in public and private sectors, integration with clinical practice.

4. Strong infrastructure in major hospitals and cancer centers, some regional disparities.

3. Moderate infrastructure, primarily in private settings or research institutions.

2. Limited infrastructure, available only in select centers or for high-cost private testing.

1. Minimal or no infrastructure, testing mostly unavailable or sent abroad.

Country	Specialized Centers	Genetic & Molecular Testing Infrastructure
South Africa	3	3
Kenya	2	2
Nigeria	2	2
Egypt	2	3
Morocco	2	2
Algeria	2	2
Ethiopia	1	1
India	3	4
Japan	4	4
South Korea	4	4
China	4	4
Thailand	3	3
Singapore	4	4
United Kingdom	4	4
Germany	5	4
France	4	4
Netherlands	5	4
Sweden	5	4
Italy	4	4
Spain	4	4
Poland	4	3
Mexico	2	3
Brazil	3	3
Argentina	3	3
Chile	3	3
Colombia	2	3
United States	5	5
Canada	5	4
Australia	4	4
New Zealand	4	4
Greece	4	3
Rwanda	1	1
Uganda	1	1
Serbia	3	3
Saudi Arabia	4	4
UAE	4	4
Syria	1	1
Indonesia	2	2
Vietnam	3	3
Philippines	2	2
Russia	4	3
Malaysia	4	4

International Cancer Patient Coalition

Canada

Treatment Access, Research Funding and Awareness Campaigns



Strengths

- Canada's **universal healthcare system** ensures access to basic prostate cancer treatments, including surgery, hormone therapy, and radiotherapy.
- Strong research ecosystem with federal funding agencies and centers like the **Princess Margaret Cancer Centre and BC Cancer Agency**.

Weakness

- Newer therapies (e.g., PARP inhibitors, second-line androgen receptor blockers) may face **delays in provincial formulary approval**.
- National awareness campaigns often lack **consistent messaging** or tailored content for high-risk groups like Black or Indigenous men.

Opportunity

- Funding programs can be better aligned with **real-world evidence generation** to fast-track approvals.
- **Culturally adapted awareness** programs can drive better screening uptake among underrepresented populations.

Threats

- **Budget constraints** at the provincial level may limit equitable drug access.
- The growing cost of immunotherapies and precision oncology could challenge the sustainability of universal access.

5. Strong healthcare infrastructure with comprehensive treatment access, high research funding, and nationwide awareness campaigns. Patients have access to advanced therapies, clinical trials, and widespread early detection programs.

4. Well-developed system with good treatment availability, strong research funding, and effective but regionally focused awareness campaigns. Some disparities may exist in rural areas or between public and private sectors.

3. Moderate development, with specialized treatments available in major hospitals, research funding concentrated on specific cancers, and occasional but limited awareness efforts. Healthcare access may be restricted by cost or geography.

2. Limited system where cancer treatment is available only in select urban centers, research funding is minimal or sporadic, and awareness campaigns are rare or underfunded. Patients often face long wait times or financial barriers.

1. Poor infrastructure with severe barriers to treatment, little to no research funding, and lack of structured awareness campaigns. Cancer care is largely inaccessible, with many patients relying on out-of-pocket expenses or external aid.

Country	Treatment Access	Research Funding	Awareness Campaigns
South Africa	3	3	3
Kenya	1	1	1
Nigeria	1	1	1
Egypt	2	2	2
Morocco	2	2	2
Algeria	2	2	2
Ethiopia	1	1	1
India	3	3	3
Japan	4	4	5
South Korea	4	4	5
China	3	3	3
Thailand	2	3	2
Singapore	4	5	5
United Kingdom	4	5	5
Germany	5	5	5
France	4	4	4
Netherlands	5	5	5
Sweden	5	5	5
Italy	4	4	4
Spain	4	4	4
Poland	3	3	3
Mexico	2	3	3
Brazil	2	3	3
Argentina	2	3	3
Chile	2	3	3
Colombia	1	2	3
United States	5	5	5
Canada	5	5	5
Australia	4	4	4
New Zealand	3	3	3
Greece	3	3	3
Rwanda	1	1	1
Uganda	1	1	1
Serbia	2	3	3
Saudi Arabia	4	4	4
UAE	4	4	4
Syria	1	1	1
Indonesia	2	2	2
Vietnam	2	2	3
Philippines	2	2	3
Russia	4	4	4
Malaysia	3	2	3

International Cancer Patient Coalition

Canada

Survival Rates, Early Detection and Palliative Care



Strengths

- **Five-year survival** for localized prostate cancer exceeds **95%**, among the highest globally.
- Well-integrated palliative care services in major hospitals, with provincial end-of-life care strategies in place.

Weakness

- Despite high survival, men in **rural or northern areas are more likely to present with advanced-stage disease**.
- Variability in **early detection practices** across provinces contributes to inconsistent diagnosis timelines.

S W O T

Opportunity

- Deploy **risk-adapted screening** to catch aggressive disease earlier while minimizing overtreatment.
- Expand community-based **palliative care teams**, especially in rural settings.

Threats

- Aging population may **overwhelm existing palliative care** services.
- If early detection continues to be inconsistent, **stage migration** could increase.

5. High survival rates, strong early detection programs, and well-established palliative care services. Patients have access to timely diagnosis, advanced treatments, and comprehensive end-of-life care.

4. Good survival rates, effective early detection efforts, and accessible but regionally limited palliative care. Some disparities may exist in rural areas or for specific cancer types.

3. Moderate survival rates, early detection available but not widespread, and palliative care services mainly in urban centers. Some patients experience delays in diagnosis or limited end-of-life care.

2. Low survival rates, early detection efforts are inconsistent or underfunded, and palliative care is minimal or only available in select hospitals. Cancer patients face significant access barriers.

1. Very low survival rates, poor early detection infrastructure, and almost no palliative care services. Many patients are diagnosed late and lack proper support for pain management and end-of-life care.

Country	Survival Rates	Early Detection	Palliative Care
South Africa	2	3	2
Kenya	1	1	1
Nigeria	1	1	1
Egypt	2	2	2
Morocco	2	2	2
Algeria	2	2	2
Ethiopia	1	1	1
India	3	3	3
Japan	5	4	5
South Korea	5	4	4
China	3	3	4
Thailand	2	2	2
Singapore	5	5	5
United Kingdom	5	5	5
Germany	5	5	5
France	5	4	4
Netherlands	5	5	5
Sweden	5	5	5
Italy	5	4	5
Spain	5	4	5
Poland	3	3	3
Mexico	2	2	2
Brazil	3	3	3
Argentina	3	3	3
Chile	3	3	3
Colombia	2	2	2
United States	5	5	5
Canada	5	5	5
Australia	5	4	4
New Zealand	4	4	3
Greece	3	3	3
Rwanda	1	1	1
Uganda	1	1	1
Serbia	2	3	2
Saudi Arabia	4	4	4
UAE	4	4	4
Syria	1	1	1
Indonesia	2	2	2
Vietnam	2	2	2
Philippines	2	2	2
Russia	4	4	3
Malaysia	3	2	3

International Cancer Patient Coalition

Canada

Utilization of Biomarkers



Strengths

- Canadian cancer centers use **genomic classifiers and molecular tests** (e.g., Decipher, Oncotype DX) to guide treatment in select cases.
- PSA screening and monitoring are standard across all provinces.

Weakness

- Access to **advanced biomarker tests is not uniform**, often restricted to academic or private settings.
- Biomarker use is **not yet standard** practice in early risk stratification across all health systems.

S W O T

Opportunity

- Create national pathways to **integrate biomarkers** into prostate cancer guidelines and reimbursement lists.
- Expand **clinical trials using genomic profiling** to diversify the patient population and improve applicability.

Threats

- **Cost barriers** and slow adoption of new technologies may widen the gap between public and private care settings.
- Overdependence on PSA can lead to **overdiagnosis of indolent cancers**.

Moderate utilization, often restricted to major hospitals or private healthcare settings. Some patients may not receive biomarker testing due to cost or limited availability in public healthcare systems.

Biomarker testing is available but underutilized, with significant barriers such as high costs, lack of awareness, or limited infrastructure. Many patients may not receive recommended biomarker assessments.

Biomarker testing is rarely performed, often due to lack of infrastructure, awareness, or financial barriers. Patients typically do not receive targeted therapies based on biomarker status.



International Cancer Patient Coalition

Canada

Clinical Guidelines



Strengths

- Canada follows **evidence-based national guidelines** via the Canadian Urological Association and provincial cancer agencies.
- Guidelines are updated regularly and incorporate **active surveillance, mpMRI, and risk-based management**.

Weakness

- Clinical guideline implementation may vary across provinces, particularly in community clinics and rural settings.
- **Limited monitoring or enforcement** mechanisms for guideline compliance.

S W O T

Opportunity

- Use of **clinical decision-support tools** within electronic medical records can help standardize adherence.
- Translate guidelines into **patient-friendly formats** to support shared decision-making.

Threats

- **Variation in care practices** despite national guidelines may result in inequity of outcomes.
- Resistance to de-escalation of treatment in low-risk cases may persist among some providers.

	Very High	High	Medium	Low	Very Low
Clinical Guideline Implementation	O	✖	✖	✖	✖
Feasibility of Integration	O	✖	✖	✖	✖
Adoption of International Guidelines	O	✖	✖	✖	✖
Engagement with Updates	✖	O	✖	✖	✖
ESMO Guidelines Implementation	O	✖	✖	✖	✖

International Cancer Patient Coalition

Canada

Reimbursement

Strengths

- Essential prostate cancer treatments are covered under the provincial health insurance plans.
- Some **biomarker testing and targeted therapies** are reimbursed in high-risk or metastatic cases depending on province.

Weakness

- Delayed inclusion of **new drugs** into provincial formularies compared to international counterparts.
- Lack of **uniform reimbursement** for emerging technologies and tests across Canada.

S W O T

Opportunity

- Streamline **Health Canada and provincial HTA** approval processes to speed access.
- Integrate **real-world data** into reimbursement decisions to reflect Canadian practice environments.

Threats

- Rising drug prices may **strain public health budgets**, potentially impacting coverage for new therapies.
- Interprovincial disparities in reimbursement could drive **inequity in care**.

● A structured reimbursement system exists, ensuring biomarker testing is covered through national healthcare systems, insurance, or public-private partnerships. Patients face no direct financial burden.

● A reimbursement framework is in place, but patients may still have out-of-pocket expenses such as co-pays, limited coverage, or financial caps on testing.

● No formal reimbursement system exists, meaning patients must fully cover the cost of biomarker testing out-of-pocket.

Country	Reimbursement Framework	No-cost Access
United States	●	○
United Kingdom	●	●
Canada	●	●
Australia	●	●
Germany	●	●
France	●	●
Netherlands	●	●
Sweden	●	●
Italy	●	●
Spain	●	●
Poland	●	●
Japan	●	●
South Korea	●	●
China	●	●
India	○	○
Singapore	●	●
Thailand	●	●
South Africa	○	○
Kenya	○	○
Nigeria	○	○
Egypt	○	○
Morocco	○	○
Algeria	●	●
Ethiopia	○	○
Mexico	●	●
Brazil	●	●
Argentina	●	●
Chile	●	●
Colombia	●	●
New Zealand	●	●
Greece	●	●
Rwanda	○	○
Uganda	○	○
Serbia	●	●
Saudi Arabia	●	●
UAE	●	●
Syria	○	○
Indonesia	●	○
Vietnam	●	○
Philippines	○	○
Russia	●	●
Malaysia	●	●

International Cancer Patient Coalition

Canada

Prostate Cancer Screening

Strengths

- PSA testing is widely available and recommended as a shared decision-making tool for men over 50.
- Efforts to promote **informed screening** are supported by primary care providers and provincial programs.

Weakness

- Canada lacks a **national organized screening program**, leading to inconsistent uptake.
- Low screening rates among **Black men, Indigenous men, and newcomers** due to limited cultural adaptation.

S W O T

Opportunity

- Develop a **national risk-adapted screening protocol** targeting high-risk groups starting from age 45.
- Use AI-based tools and EMRs to identify eligible men who haven't been screened.

Threats

- Ongoing debates about PSA testing could lead to **confusion among clinicians and patients**.
- Missed opportunities for early detection may result in **higher treatment costs and burden**.

Country	Prostate Cancer Screening
United States	Annual LDCT (50-80 years, high-risk smokers)
United Kingdom	LDCT for high-risk individuals (55-74 years)
Canada	LDCT for high-risk individuals (55-74 years)
Australia	No national program, high-risk groups advised LDCT
Germany	No national program, under evaluation
France	No national LDCT screening
Netherlands	Participating in European screening studies
Sweden	No national LDCT screening
Italy	Regional pilot LDCT screening
Spain	No national LDCT program
Poland	No national program
Japan	No national LDCT program
South Korea	LDCT for high-risk individuals (50-74 years)
China	No national LDCT program
India	No national LDCT program
Singapore	No national LDCT program
Saudi Arabia	No national LDCT program; some hospital-based opportunistic screening
UAE	No national LDCT program; early-stage pilot studies ongoing in select hospitals
Syria	No national LDCT program; screening not prioritized due to conflict
Malaysia	No program; high-risk CT pilots

Country	Prostate Cancer Screening
Thailand	No national LDCT program
South Africa	No national LDCT program
Kenya	No national LDCT program
Nigeria	No national LDCT program
Egypt	No national LDCT program
Morocco	No national LDCT program
Algeria	No national LDCT program
Ethiopia	No national LDCT program
Mexico	No national LDCT program
Brazil	No national LDCT program
Argentina	No national LDCT program
Chile	No national LDCT program
Colombia	No national LDCT program
New Zealand	No national LDCT program
Greece	No national LDCT program
Rwanda	No national LDCT program
Uganda	No national LDCT program
Serbia	No national LDCT program
Indonesia	No national LDCT program; opportunistic screening in private sector
Vietnam	No national LDCT program; early pilot screening studies in Hanoi and Ho Chi Minh
Philippines	No national LDCT program; feasibility and awareness programs under discussion
Russia	No formal national LDCT program; regional pilot screening programs in large cities